Scienza Health media kit: press resources, peer-reviewed clinical research citations, platform specifications, validated performance benchmarks, and company background for GIA®, the Digital Human® that screens for 46 cognitive and neurological conditions using speech biomarker technology in post-acute and long-term care.
She Just Talked. We Found What Was Missing.
Everything journalists, analysts, and media professionals need to cover Scienza Health and the science of speech biomarker screening.
Key Facts
- Conditions
- 46
- Screening
- 40 seconds
- Results
- 60 seconds
- Dataset
- 12.3M residents
- Registration
- 510(k)
- Languages
- 92
Conditions Undetected. Care Delayed. Lives Diminished.
In post-acute and long-term care, subtle changes in cognition and behavior go unnoticed every day. Not because clinicians lack skill, but because the tools and time required to detect these changes do not exist at scale. 55 million Americans live in neurology deserts with no access to specialist screening. Facilities facing a 450,000-nurse shortage simply do not have the bandwidth.
Depression, anxiety, PTSD, cognitive decline, early Parkinson’s, and tardive dyskinesia are consistently underdetected in skilled nursing and memory care. The consequences are preventable hospitalizations, avoidable readmissions, five-star rating impacts, and residents who go without the interventions that could preserve their quality of life.
Early detection is not about a diagnosis. It is about preserving dignity, preventing harm, and giving clinicians the information they need before it is too late.
All They Have to Do Is Talk
GIA® is a Digital Human®, a clinically validated Digital Human® that conducts cognitive and neurological screenings through natural conversation, without staff involvement. She speaks 92 languages, adapts her conversation flow in real time, and completes a full clinical screening in under five minutes.
The Resident Speaks
GIA® greets the resident by name in their preferred language and guides them through a brief, comfortable conversation. The resident talks for approximately 40 seconds.
2,500 Biomarkers Analyzed
GIA®’s Large Acoustic Model captures acoustic patterns, vocal tremor, prosody, pause duration, phonation, and speech cadence. It analyzes 2,500+ speech biomarkers in real time.
Conditions Flagged
Within 60 seconds, GIA® flags potential indicators of depression, anxiety, PTSD, cognitive decline, Parkinson’s, and other conditions across 46 screening categories.
Clinician Reviews
The reviewing clinician receives a concise summary: results, clinical notes, full transcript, and resident video. Review takes under 2 minutes.
EHR Updated
With clinician approval, results and documentation write directly back to the EHR. Fully integrated with PointClickCare and live in their Marketplace. No manual documentation.
Human-in-the-Loop
GIA® cannot submit results to the EHR. Only the clinician can. This is not a policy. It is how the platform was architected. Where clinical technology is increasingly autonomous, Scienza built the opposite: a system where the human always decides.
Peer-Reviewed. Not Vendor Claims.
Independent validation from institutions that do not lend their names lightly. See the full clinical research library for all 19 peer-reviewed studies.
AUC 0.97. Peer-reviewed. Beth Israel Deaconess Medical Center and UMass Chan Medical School.
Peer-reviewed and clinically validated. Japan’s National Cerebral and Cardiovascular Center.
MIT, Mayo Clinic, Vanderbilt University Medical Center, King’s College London. Multi-institutional research on speech as a biomarker for disease.
81.6% accuracy.
80.0% accuracy.
77.5% accuracy.
70.8% accuracy.
Real-World Benchmarks
These figures reflect validated clinical and operational performance across real-world deployments, not laboratory conditions.
Clinically meaningful accuracy for non-invasive screening
From ~30 minutes manual to ~8 minutes with Scienza
Across voice and video modalities
Automated outbound calls, no staff involvement
Across completed Digital Human interactions
Reduction in documentation and administrative burden
The Architecture Behind GIA®
Built on a Foundation of Trust
GIA® operates within a clinical governance framework spanning 14 domains: HIPAA-native data handling, impossible response detection, real-time safety escalation for suicidal ideation and abuse disclosure, demographic bias auditing, and tamper-proof audit trails. Every guardrail is verified against 8 defined test cases before production deployment. All 8 must pass.
Quarterly performance audits are disaggregated by age, gender, race, ethnicity, and language. Any group showing greater than a 5% performance differential triggers immediate investigation.
Safety is not a feature. It is the foundation.
Why This Matters
55 million Americans live in neurology deserts with no access to specialist cognitive screening.
450,000-nurse shortage in post-acute care. The workforce crisis is structural, not cyclical.
8 cognitive assessments per resident per year in the average post-acute facility, each one consuming clinician time that barely exists.
Post-acute care carries the highest documentation burden in healthcare. Clinicians spend more time on paperwork than with residents.
Depression, cognitive decline, and early Parkinson’s are systematically underdetected in skilled nursing and memory care, leading to preventable hospitalizations and avoidable readmissions.
Scienza Health
Scienza Health builds clinically validated speech biomarker technology for post-acute and long-term care. The company’s Digital Human®, GIA®, powered by digitalhumanOS™, screens for 46 cognitive and neurological conditions using 40 seconds of natural speech. No staff required. Results written directly to the EHR.
Founded by David Kaiser, who grew up as a caregiver for his grandmother and mother before spending 20 years in healthcare and technology. He built Scienza to solve the problem he witnessed firsthand: conditions going undetected in the people who could least afford to wait. Headquartered in Newport Beach, California.
Questions Journalists Ask
What does GIA® screen for?
GIA® screens for 46 cognitive and neurological conditions including depression, anxiety, PTSD, cognitive decline, Parkinson’s disease, and tardive dyskinesia. She analyzes 2,500+ speech biomarkers in approximately 40 seconds of natural conversation.
How is the technology validated?
Independent peer-reviewed research from Beth Israel Deaconess Medical Center, UMass Chan Medical School, and Japan’s National Cerebral and Cardiovascular Center. The NIH Bridge2AI program at MIT, Mayo Clinic, Vanderbilt, and King’s College London conducts multi-institutional research on speech as a biomarker for disease.
Does GIA® replace clinicians?
No. GIA® conducts the screening conversation, but a clinician reviews every result before anything enters the medical record. GIA® cannot submit to the EHR. Only the clinician can. This human-in-the-loop architecture is enforced at the platform level.
What EHR systems does Scienza integrate with?
Fully integrated with PointClickCare and live in their Marketplace. Additional integrations include Epic, Cerner, MatrixCare, NextGen, and Athena via HL7 FHIR and Direct API.
Get the Full Media Kit
The complete fact sheet with research citations, platform specifications, validated benchmarks, and company background.
David Kaiser
Founder & CEO, Scienza Health
GIA® is a registered trademark of Scienza Health, Inc. Digital Human® is a registered trademark of Scienza Health, Inc. GIA® is 510(k) registered. digitalhumanOS™ powers the clinical intelligence platform. This platform screens for clinical conditions and does not diagnose, treat, cure, or prevent any disease. All results require clinician review.